Combination therapy using a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and thiazolidinedione was linked to significantly lower risks of all-cause mortality, major cardiovascular events, and cardiovascular death in patients with type 2 diabetes (T2D).
Real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes. | Image credit: Minerva Studio – stock.adobe.com
The retrospective cohort study is published in JAMA Network Open.
“We explored the cardiovascular outcomes of various diabetes treatments, focusing on combining a GLP-1 RA and thiazolidinedione compared with monotherapies,” wrote the researchers of the study. “This study highlights that the benefits of combination therapy become more pronounced with prolonged use.”
Thiazolidinediones are a class of…